A record number of patients in Scotland are waiting more than six weeks for imaging exams and treatment, according to recent statistics obtained by Scotland’s The Herald.  

“This legislation is an important step in ensuring patients are appropriately notified about their risk of breast cancer so they can make informed decisions about their care,” Dennis Durmis, chair of MITA’s Board of Directors, said in a prepared statement. 

Researchers have created a machine learning model that identified 98 percent of malignant atypical ductal hyperplasia (ADH) lesions prior to surgery, according to a single-center study published in JCO Clinical Cancer Informatics. The approach saved 16 percent of women from unnecessary surgery.

Implementing a clinical decision support (CDS) tool increased the overall appropriateness scores of CT and MRI orders, but showed no major difference between the habits of house staff and non-house staff.

Ultrasound scans of the calcaneus—or the heel bone—were equal to results gathered from dual-energy x-ray absorptiometry (DXA) for assessing bone health, according to new research published online in the March issue of The Journal of the American Osteopathic Association.  

Radiologists who interpret traditional two-dimensional (2D) mammograms required little time in transitioning to reading digital breast tomosynthesis (DBT) exams or three-dimensional (3D) mammograms, and improved their accuracy in cancer detection, according to research published online Feb. 26 in Radiology.  

“Our results may help in planning medical injury surveillance systems for future large-scale sports events tailored for each specific sport and may potentially aid in developing preventive efforts before and during competition,” wrote the authors of a Feb. 21 study published in Academic Radiology.

The technique, which combines MRI with a manganese-based contrast agent, could help researchers better understand how neurons communicate in the brain, according to the study published online Feb. 22 in Nature Communications. 

General Electric (GE) may be halting its plan for an initial public offering (IPO) of its healthcare sector in 2019, GE Chairman and CEO Larry Culp told CNBC on Feb. 25. The announcement came after the company made a deal to sell its biopharma business to Danaher for $21.4 billion.

High-Quality Medical Images Help Assess Players’ Health